EDGAR·FLOW

Pasithea Therapeutics Corp. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Pasithea announced Phase 1/1b data for PAS-004 in neurofibromatosis: all 15 evaluable participants showed cutaneous neurofibroma (cNF) reductions with median 41% at all doses and 46% at planned Phase 2 doses (4–12mg); reductions deepened to 71% at 15 cycles in the 4mg cohort. Early plexiform neurofibroma activity observed in 18 participants with two meeting partial-response threshold. FDA cleared IND for Phase 2 randomized trial (~200 patients). No serious adverse events reported; favorable safety profile with 97.6% Grade 1–2 events.
Why this rating

Early-stage biotech ($5.1M market cap) with positive clinical efficacy signal and FDA IND clearance for Phase 2—meaningful de-risking. However, early data, small cohorts, and long path to approval limit certainty; material but not transformational at this stage.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$0.49
+10 min · unknown
$0.51 ▲ 3.06%
+30 min · unknown
$0.48 ▼ 2.04%
+1 hr · unknown
$0.47 ▼ 3.88%
+4 hrs · unknown
$0.46 ▼ 6.12%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ KTTA · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.